Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (165) 165
female (110) 110
male (103) 103
middle aged (102) 102
adult (101) 101
hematology (85) 85
aged (50) 50
oncology (50) 50
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
transplantation, autologous (47) 47
adolescent (46) 46
index medicus (38) 38
bone marrow transplantation (37) 37
transplantation (32) 32
combined modality therapy (30) 30
chemotherapy (29) 29
hematopoietic stem cell transplantation (29) 29
treatment outcome (24) 24
child (22) 22
survival (20) 20
cytarabine - administration & dosage (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - therapy (18) 18
remission induction (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
care and treatment (16) 16
disease-free survival (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (16) 16
therapy (16) 16
stem cells (15) 15
transplantation, homologous (15) 15
chronic myelogenous leukemia (14) 14
immunology (14) 14
prognosis (14) 14
endocrinology & metabolism (13) 13
etoposide - administration & dosage (13) 13
follow-up studies (13) 13
hematopoietic stem cells (13) 13
hodgkin disease - therapy (13) 13
retrospective studies (13) 13
animals (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (12) 12
clinical trials as topic (12) 12
health aspects (12) 12
idarubicin - administration & dosage (12) 12
italy (12) 12
acute disease (11) 11
antineoplastic agents - therapeutic use (11) 11
bone-marrow transplantation (11) 11
child, preschool (11) 11
hematopoietic stem cell transplantation - methods (11) 11
leukapheresis (11) 11
leukemia, myeloid, acute - therapy (11) 11
recurrence (11) 11
survival rate (11) 11
leukemia, myeloid, acute - surgery (10) 10
lymphomas (10) 10
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (10) 10
precursor cell lymphoblastic leukemia-lymphoma - therapy (10) 10
research (10) 10
time factors (10) 10
aged, 80 and over (9) 9
cancer (9) 9
cyclophosphamide - administration & dosage (9) 9
diagnosis (9) 9
granulocyte colony-stimulating factor - therapeutic use (9) 9
medicine & public health (9) 9
multiple myeloma (9) 9
prospective studies (9) 9
rituximab (9) 9
survival analysis (9) 9
bone-marrow-transplantation (8) 8
chronic myeloid-leukemia (8) 8
dosage and administration (8) 8
hodgkin disease - drug therapy (8) 8
idarubicin (8) 8
leukemia (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - genetics (8) 8
leukemia, myeloid, acute - drug therapy (8) 8
leukemia, myeloid, acute - mortality (8) 8
multiple myeloma - mortality (8) 8
myelodysplastic syndromes (8) 8
patient outcomes (8) 8
prednisone - administration & dosage (8) 8
relapse (8) 8
remission (8) 8
salvage therapy (8) 8
stem cell transplantation (8) 8
stem-cell transplantation (8) 8
young adult (8) 8
acute myelogenous leukemia (7) 7
age factors (7) 7
cyclophosphamide (7) 7
doxorubicin - administration & dosage (7) 7
drug therapy (7) 7
drug therapy, combination (7) 7
gene expression (7) 7
hodgkin disease - surgery (7) 7
infant (7) 7
interferon-alpha - therapeutic use (7) 7
leukemia - drug therapy (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis
by Gay, F and Oliva, S and Petrucci, M.T and Montefusco, V and Conticello, C and Musto, P and Catalano, L and Evangelista, A and Spada, S and Campbell, P and Ria, R and Salvini, M and Offidani, M and Carella, A.M and Omedé, P and Liberati, A.M and Troia, R and Cafro, A.M and Malfitano, A and Falcone, A.P and Caravita, T and Patriarca, F and Nagler, A and Spencer, A and Hajek, R and Palumbo, A and Boccadoro, M
Leukemia, ISSN 0887-6924, 08/2017, Volume 31, Issue 8, pp. 1727 - 1734
In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus... 
MULTIPLE-MYELOMA | STANDARD CHEMOTHERAPY | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | ONCOLOGY | HIGH-DOSE THERAPY | CONSOLIDATION THERAPY | INITIAL TREATMENT | RANDOMIZED-TRIAL | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Administration, Oral | Multiple Myeloma - mortality | Humans | Middle Aged | Salvage Therapy | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Clinical Trials, Phase III as Topic | Multiple Myeloma - therapy | Adult | Aged | Thalidomide - therapeutic use | Autografts | Usage | Chemotherapy | Care and treatment | Multiple myeloma | Diagnosis | Cancer | Salvage | Medical prognosis | Melphalan | Clinical trials | Myeloma | Patients | Survival
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi
by Luminari, S and Biasoli, I and Arcaini, L and Versari, A and Rusconi, C and Merli, F and Spina, M and Ferreri, A.J.M and Zinzani, P.L and Gallamini, A and Mastronardi, S and Boccomini, C and Gaidano, G and D'Arco, A.M and Di Raimondo, F and Carella, A.M and Santoro, A and Musto, P and Federico, M
Annals of Oncology, ISSN 0923-7534, 08/2013, Volume 24, Issue 8, pp. 2108 - 2112
The role of [F-18] fluorodeoxyglucose (FDG)-positron emission tomography (PET) in follicular lymphoma (FL) staging is not yet determined. The aim of the... 
FDG-PET | Follicular lymphoma | Staging | CT scan | INTERIM | MANAGEMENT | follicular lymphoma | RESPONSE CRITERIA | NON-HODGKINS-LYMPHOMAS | CLASSIFICATION | IMPACT | POSITRON-EMISSION-TOMOGRAPHY | INTERNATIONAL WORKSHOP | THERAPY | ONCOLOGY | SCAN | staging | Doxorubicin - therapeutic use | Prognosis | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Positron-Emission Tomography | Cyclophosphamide - therapeutic use | Neoplasm Staging - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Follicular - diagnostic imaging | Neoplasm Metastasis - diagnosis | Vincristine - therapeutic use | Adult | Female | Fluorodeoxyglucose F18 | Italy | Aged | Retrospective Studies | Radiopharmaceuticals | Prednisone - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
by Palumbo, Antonio and Cavallo, Federica and Gay, Francesca and Di Raimondo, Francesco and Ben Yehuda, Dina and Petrucci, Maria Teresa and Pezzatti, Sara and Caravita, Tommaso and Cerrato, Chiara and Ribakovsky, Elena and Genuardi, Mariella and Cafro, Anna and Marcatti, Magda and Catalano, Lucio and Offidani, Massimo and Carella, Angelo Michele and Zamagni, Elena and Patriarca, Francesca and Musto, Pellegrino and Evangelista, Andrea and Ciccone, Giovannino and Omedé, Paola and Crippa, Claudia and Corradini, Paolo and Nagler, Arnon and Boccadoro, Mario and Cavo, Michele
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
by Lo-Coco, Francesco and Avvisati, Giuseppe and Vignetti, Marco and Thiede, Christian and Orlando, Sonia Maria and Iacobelli, Simona and Ferrara, Felicetto and Fazi, Paola and Cicconi, Laura and Di Bona, Eros and Specchia, Giorgina and Sica, Simona and Divona, Mariadomenica and Levis, Alessandro and Fiedler, Walter and Cerqui, Elisa and Breccia, Massimo and Fioritoni, Giuseppe and Salih, Helmut R and Cazzola, Mario and Melillo, Lorella and Carella, Angelo M and Brandts, Christian H and Morra, Enrica and von Lilienfeld-Toal, Marie and Hertenstein, Bernd and Wattad, Mohammed and Lübbert, Michael and Hänel, Matthias and Schmitz, Norbert and Link, Hartmut and Kropp, Maria Grazia and Rambaldi, Alessandro and La Nasa, Giorgio and Luppi, Mario and Ciceri, Fabio and Finizio, Olimpia and Venditti, Adriano and Fabbiano, Francesco and Döhner, Hartmut and Döhner, Konstanze and Sauer, Michaela and Ganser, Arnold and Amadori, Sergio and Mandelli, Franco and Ehninger, Gerhard and Schlenk, Richard F and Platzbecker, Uwe and Study Alliance Leukemia and Grp Italiano Malattie Ematologiche and German-Austrian Acute Myeloid and German-Austrian Acute Myeloid Leukemia Study Group and Gruppo Italiano Malattie Ematologiche dell'Adulto
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
All- trans retinoic acid (ATRA) plus arsenic trioxide was found to be noninferior to ATRA plus chemotherapy, and less toxic, in the treatment of acute... 
TRIAL | FRONT-LINE THERAPY | RELAPSE | MEDICINE, GENERAL & INTERNAL | POLYMERASE-CHAIN-REACTION | ANTHRACYCLINE | CONSOLIDATION THERAPY | RISK | FUSION GENE TRANSCRIPTS | MINIMAL-RESIDUAL-DISEASE | CHEMOTHERAPY | Oxides - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Consolidation Chemotherapy | Thrombocytopenia - chemically induced | Oxides - adverse effects | Young Adult | Disease-Free Survival | Arsenicals - therapeutic use | Tretinoin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tretinoin - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Leukemia, Promyelocytic, Acute - genetics | Neutropenia - chemically induced | Arsenicals - adverse effects | Leukemia, Promyelocytic, Acute - drug therapy | Dosage and administration | Drug therapy, Combination | Research | Tretinoin | Arsenic | Toxicity | Leukemia | Arsenic trioxide | Patients | Studies | Promyeloid leukemia | Chemotherapy | Consolidation | Remission | Pharmaceutical industry | Drug therapy | Retinoic acid | Acute promyeloid leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Interferon-alpha (IFN-a) Given Alone to CML Patients with Undetectable Disease after Imatinib (IM) Is Able To Maintain Their Complete Molecular Remission after IM Discontinuation
by Carella, A.M
Blood, ISSN 0006-4971, 11/2007, Volume 110, Issue 11, pp. 4555 - 4555
Cytotoxic lymphocytes (CTLs) which recognize distinct antigenic peptides on CML cells, contributed greatly to the cure after allografting. Previously, BCR-ABL... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
by Cavallo, F and Bringhen, S and Milone, G and Ben-Yehuda, D and Nagler, A and Calabrese, E and Cascavilla, N and Montefusco, V and Lupo, B and Liberati, A.M and Crippa, C and Rossini, F and Passera, R and Patriarca, F and Cafro, A.M and Omedè, P and Carella, A.M and Peccatori, J and Catalano, L and Caravita, T and Musto, P and Petrucci, M.T and Boccadoro, M and Palumbo, A
Leukemia, ISSN 0887-6924, 10/2011, Volume 25, Issue 10, pp. 1627 - 1631
Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells for autologous stem cell transplantation, especially after... 
myeloma | novel agent | lenalidomide | mobilization | transplantation | COLLECTION | COMBINATION THERAPY | BORTEZOMIB | BLOOD PROGENITOR CELLS | CHEMOTHERAPY | TRIAL | CD34(+) CELLS | THALIDOMIDE PLUS DEXAMETHASONE | ONCOLOGY | HEMATOLOGY | Thalidomide - analogs & derivatives | Humans | Middle Aged | Antineoplastic Agents | Female | Male | Hematopoietic Stem Cell Mobilization | Thalidomide - therapeutic use | Transplantation Conditioning | Cyclophosphamide | Care and treatment | Granulocyte colony-stimulating factor | Multiple myeloma | Physiological aspects | Research | Diagnosis | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
by Tiacci, Enrico and Park, Christopher Y and Park, Jae H and De Carolis, Luca and Chung, Young R and Chung, Stephen S and Broccoli, Alessandro and Scott, Sasinya and Zaja, Francesco and Devlin, Sean and Pulsoni, Alessandro and Cimminiello, Michele and Kim, Eunhee and Rossi, Davide and Stone, Richard M and Motta, Giovanna and Saven, Alan and Varettoni, Marzia and Altman, Jessica K and Anastasia, Antonella and Grever, Michael R and Ambrosetti, Achille and Rai, Kanti R and Fraticelli, Vincenzo and Lacouture, Mario E and Carella, Angelo M and Levine, Ross L and Leoni, Pietro and Rambaldi, Alessandro and Falzetti, Franca and Ascani, Stefano and Capponi, Monia and Martelli, Maria P and Pileri, Stefano A and Rosen, Neal and Foà, Robin and Berger, Michael F and Zinzani, Pier L and Abdel-Wahab, Omar and Falini, Brunangelo and Tallman, Martin S
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, pp. 1733 - 1747
Tiacci, Falini, and colleagues discovered BRAF mutations in nearly all patients with hairy-cell leukemia. Now, their group, along with U.S. investigators, has... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | ACTIVATION | MELANOMA | MEK INHIBITION | RAF | PHENOTYPE | MUTATIONS | SIGNATURE | VEMURAFENIB | CLADRIBINE | Recurrence | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Arthralgia - chemically induced | Indoles - administration & dosage | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Aged, 80 and over | Adult | Female | Leukemia, Hairy Cell - pathology | Administration, Oral | Leukemia, Hairy Cell - genetics | Proto-Oncogene Proteins - genetics | Biomarkers - blood | Remission Induction | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Bone Marrow - pathology | Leukemia, Hairy Cell - drug therapy | Sulfonamides - adverse effects | Aged | Mutation | Sulfonamides - administration & dosage | Vemurafenib | Care and treatment | Health aspects | Leukemia, Hairy cell | Inhibitor drugs | Leukemia | Arthralgia | Genes | Clinical trials | Extracellular signal-regulated kinase | Bone marrow | Arthritis | Kinases | Patients | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
by Larocca, A and Bringhen, S and Petrucci, M.T and Oliva, S and Falcone, A.P and Caravita, T and Villani, O and Benevolo, G and Liberati, A.M and Morabito, F and Montefusco, V and Passera, R and De Rosa, L and Omedé, P and Vincelli, I.D and Spada, S and Carella, A.M and Ponticelli, E and Derudas, D and Genuardi, M and Guglielmelli, T and Nozzoli, C and Aghemo, E and De Paoli, L and Conticello, C and Musolino, C and Offidani, M and Boccadoro, M and Sonneveld, P and Palumbo, A
Leukemia, ISSN 0887-6924, 06/2016, Volume 30, Issue 6, pp. 1320 - 1326
This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients. 75 years with newly diagnosed multiple myeloma... 
MELPHALAN-PREDNISONE | SURVIVAL | MAINTENANCE | DEXAMETHASONE | METAANALYSIS | THERAPY | ONCOLOGY | CLINICAL-TRIALS | LENALIDOMIDE | INITIAL TREATMENT | PLUS THALIDOMIDE | HEMATOLOGY | Prednisone - administration & dosage | Multiple Myeloma - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Survival Rate | Disease-Free Survival | Cyclophosphamide | Melphalan - administration & dosage | Multiple Myeloma - drug therapy | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Female | Aged | Dose-response relationship (Biochemistry) | Bortezomib | Patient outcomes | Multiple myeloma | Physiological aspects | Aged patients | Drug therapy | Chemotherapy | Usage | Care and treatment | Dosage and administration | Diagnosis | Drug therapy, Combination | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
by Gahrton, G and Iacobelli, S and Bjorkstrand, B and Hegenbart, U and Gruber, A and Greinix, H and Volin, L and Narni, F and Carella, A.M and Beksac, M and Bosi, A and Milone, G and Corradini, P and Schonland, S and Friberg, K and Biezen, A. van and Goldschmidt, H and Witte, T.J.M. de and Morris, C and Niederwieser, D and Garderet, L and Kroger, N and EBMT Chronic Malignancies Working and EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 25, pp. 5055 - 5063
Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial.... 
TRIAL | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | DONOR | NEWLY-DIAGNOSED MYELOMA | AUTOGRAFT | FOLLOW-UP | MARROW-TRANSPLANTATION | HEMATOLOGY | VERSUS-HOST-DISEASE | LENALIDOMIDE MAINTENANCE | SURVIVAL CURVES | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Treatment Outcome | Time | Transplantation, Autologous - methods | Hematopoietic Stem Cell Transplantation - mortality | Disease-Free Survival | Female | Aged | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Multiple Myeloma - surgery | Transplantation, Homologous - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study
by Voso, M.T and Leone, G and Piciocchi, A and Fianchi, L and Santarone, S and Candoni, A and Criscuolo, M and Masciulli, A and Cerqui, E and Molteni, A and Finelli, C and Parma, M and Poloni, A and Carella, A.M and Spina, F and Cortelezzi, A and Salvi, F and Alessandrino, E.P and Rambaldi, A and Sica, S
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1547 - 1553
Background: Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly... 
hypomethylating treatment | allogeneic stem-cell transplantation | high-risk MDS | azacitidine | SURVIVAL | AML | PROGNOSTIC SCORING SYSTEM | EFFICACY | CLASSIFICATION | CHEMOTHERAPY | CONVENTIONAL CARE REGIMENS | ONCOLOGY | MDS | AGE | Azacitidine - adverse effects | Prospective Studies | Humans | Middle Aged | Male | Hematopoietic Stem Cell Transplantation - mortality | Transplantation Conditioning - mortality | Transplantation, Homologous | Antimetabolites, Antineoplastic - administration & dosage | Feasibility Studies | Young Adult | Myelodysplastic Syndromes - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Leukemia, Myelomonocytic, Chronic - pathology | Transplantation Conditioning - methods | Leukemia, Myeloid, Acute - therapy | Azacitidine - administration & dosage | Drug Administration Schedule | Leukemia, Myeloid, Acute - pathology | Leukemia, Myelomonocytic, Chronic - mortality | Risk Factors | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - adverse effects | Leukemia, Myelomonocytic, Chronic - therapy | Myelodysplastic Syndromes - mortality | Survival Analysis | Italy | Aged | Myelodysplastic Syndromes - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors
by Carella, A M and Corradini, P and Mussetti, A and Ricardi, U and Vitolo, U and Viviani, S
Annals of Hematology, ISSN 0939-5555, 8/2018, Volume 97, Issue 8, pp. 1301 - 1315
The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of... 
New salvage treatments | Oncology | Allografting | Medicine & Public Health | Hematology | Relapsed/refractory Hodgkin lymphoma | BONE-MARROW-TRANSPLANTATION | PD-1 BLOCKADE | PHASE-II | STAGE-III | WORKING PARTY | RADIATION-THERAPY | POSITRON-EMISSION-TOMOGRAPHY | POSTTRANSPLANTATION CYCLOPHOSPHAMIDE | RESPONSE-ADAPTED THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Antineoplastic Agents, Immunological - administration & dosage | Doxorubicin - therapeutic use | Immunomodulation - drug effects | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Positron-Emission Tomography | Vinblastine - therapeutic use | Molecular Targeted Therapy | Immunoconjugates - administration & dosage | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Immunoconjugates - therapeutic use | Immunoconjugates - adverse effects | Hodgkin Disease - diagnosis | Treatment Outcome | Combined Modality Therapy | Bleomycin - adverse effects | Retreatment | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - immunology | Neoplasm Staging | Doxorubicin - adverse effects | Care and treatment | Lymphomas | Transplantation | Drug therapy | Stem cells | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Differences among young adults, adults and elderly chronic myeloid leukemia patients
by Castagnetti, Fausto and Gugliotta, G and Baccarani, M and Breccia, M and Specchia, G and Levato, L and Abruzzese, E and Rossi, G and Iurlo, A and Martino, B and Pregno, P and Stagno, F and Cuneo, A and Bonifacio, M and Gobbi, M and Russo, D and Gozzini, A and Tiribelli, M and De Vivo, A and Alimena, G and Cavo, M and Martinelli, G and Pane, F and Saglio, G and Rosti, G and Salvi, F and Pini, M and Leoni, P and Rupoli, S and Galieni, P and Bigazzi, C and Cantore, N and Palmieri, F and Albano, F and Russo Rossi, A and Rambaldi, A and Intermesoli, T and Palandri, F and Testoni, N and Luatti, S and Soverini, S and Iacobucci, I and Bochicchio, M.T and Apolinari, M and Fogli, M and Cervello, I and Capucci, A and Malagola, M and Malpignano, A and Girasoli, M and Angelucci, E and Usala, E and Storti, S and De Biasi, E and Tagariello, G and Sartori, R and Di Raimondo, F and Vigneri, P and Impera, S and Molica, S and Lanza, F and Viganò, C and Grasso, M and Rapezzi, D and Cavazzini, F and Bosi, A and Santini, V and Capalbo, S.F and Spinosa, G and Pierri, I and Bergamaschi, M and Carella, A.M and Bacigalupo, A and De Blasio, A and Ciccone, F and Di Renzo, N and Musolino, C and Russo, S and Cortelezzi, A and Morra, E and Pungolino, E.M and Luppi, M and Marasca, R and Pogliani, E.M and Gambacorti-Passerini, C and Luciano, L and Ferrara, F and Annunziata, M and Latte, G and Noli, D and Rege-Cambrin, G and Fava, C and Semenzato, G and Binotto, G and Fabbiano, F and Turri, D and Siragusa, S and Caracciolo, C and Musso, M and Porretto, F and ... and GIMEMA CML Working Party
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 185 - 192
The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where... 
Prognosis | Young adults | Chronic myeloid leukemia | Tyrosine kinase inhibitors | BCR-ABL | CHRONIC MYELOGENOUS LEUKEMIA | SURVIVAL | DIAGNOSIS | MANAGEMENT | BONE-MARROW | CHILDHOOD CML | IMATINIB TREATMENT | prognosis | EUROPEAN-LEUKEMIANET | tyrosine kinase inhibitors | ONCOLOGY | RECOMMENDATIONS | young adults | CLINICAL-TRIALS | chronic myeloid leukemia | Prospective Studies | Age Factors | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Young Adult | Protein Kinase Inhibitors - therapeutic use | Splenomegaly - epidemiology | Aged, 80 and over | Adult | Female | Aged | Spleen - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights